A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker testsNoëlle Warmenhoven, Oskar Hansson, Gemma Salvadó et al.|Brain|2024Cited by 95
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J. Bateman, Bruno Dubois, Anna Santacruz et al.|The Lancet Neurology|2025Cited by 39
α‐Synuclein seed amplification assay detects Lewy body co‐pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on Lewy pathology burdenJohannes Levin, Simone Baiardi, Corinne Quadalti et al.|Alzheimer s & Dementia|2024Cited by 37
Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional studyJulie K. Wisch, Beau M. Ances, Nicole S. McKay et al.|The Lancet Neurology|2024Cited by 35